{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:45:43Z","timestamp":1794440743753,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270767"],"award-info":[{"award-number":["82270767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.transci.2025.104130","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T13:38:02Z","timestamp":1748266682000},"page":"104130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficiency and safety of granulocyte colony-stimulating factor combined with plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in light chain amyloidosis"],"prefix":"10.1016","volume":"64","author":[{"given":"Mengnan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhou","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-9426","authenticated-orcid":false,"given":"Xianghua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.transci.2025.104130_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.transci.2025.104130_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2023.2295221","article-title":"Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma","volume":"31","author":"Schreiner","year":"2024","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.transci.2025.104130_bib3","doi-asserted-by":"crossref","first-page":"2227425","DOI":"10.1080\/07853890.2023.2227425","article-title":"Diagnosis for Chinese patients with light chain amyloidosis: a scoping review","volume":"55","author":"Chen","year":"2023","journal-title":"Ann Med"},{"issue":"9","key":"10.1016\/j.transci.2025.104130_bib4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17474086.2022.2115353","article-title":"Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner\u2019s perspective","volume":"15","author":"Bomsztyk","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"10.1016\/j.transci.2025.104130_bib5","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41409-023-01938-0","article-title":"On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone","volume":"58","author":"Hubben","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.transci.2025.104130_bib6","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/s41409-022-01789-1","article-title":"Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells","volume":"57","author":"Kuang","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.transci.2025.104130_bib7","first-page":"475","article-title":"A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation","volume":"50","author":"Bittrich","year":"2023","journal-title":"Transfus Med Hemother"},{"issue":"2","key":"10.1016\/j.transci.2025.104130_bib8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.transci.2015.09.001","article-title":"Spontaneous splenic rupture following stem cell mobilization with G-CSF and plerixafor in AL amyloidosis","volume":"54","author":"Lessi","year":"2016","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"10.1016\/j.transci.2025.104130_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-016-2156-2","article-title":"New agents in HSC mobilization","volume":"105","author":"Domingues","year":"2017","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.transci.2025.104130_bib10","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2005-02-0468","article-title":"The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone","volume":"106","author":"Flomenberg","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.transci.2025.104130_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbmt.2011.12.578","article-title":"New hope for mobilization failures \u2026 again","volume":"18","author":"DiPersio","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"10.1016\/j.transci.2025.104130_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.transci.2025.104130_bib13","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.transci.2025.104130_bib14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.transci.2025.104130_bib15","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/ajh.25940","article-title":"Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio","volume":"95","author":"Muchtar","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.transci.2025.104130_bib16","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/bmt.2009.370","article-title":"Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma","volume":"45","author":"Gertz","year":"2010","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104130_bib17","author":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017","journal-title":"Natl Inst Health"},{"issue":"22","key":"10.1016\/j.transci.2025.104130_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/jca.20062","article-title":"The number of CD34+\u202fcells in peripheral blood as a predictor of the CD34+\u202fyield in patients going to autologous stem cell transplantation","volume":"21","author":"Basquiera","year":"2006","journal-title":"J Clin Apher"},{"issue":"5","key":"10.1016\/j.transci.2025.104130_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bbmt.2011.10.002","article-title":"Peripheral blood CD34+\u202fcell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections","volume":"18","author":"Gambell","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104130_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101811","article-title":"An evidence-based and risk-adapted GSF versus GSF plus plerixafor mobilization strategy to obtain a sufficient CD34+\u202fcell yield in the harvest for autologous stem cell transplants","volume":"39","author":"Balint","year":"2024","journal-title":"Transl Oncol"},{"issue":"12","key":"10.1016\/j.transci.2025.104130_bib21","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bbmt.2014.08.002","article-title":"Plerixafor and Abbreviated-Course Granulocyte Colony\u2013Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis","volume":"20","author":"Dhakal","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"10.1016\/j.transci.2025.104130_bib22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jcyt.2023.02.006","article-title":"Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study","volume":"25","author":"Nakamura","year":"2023","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.transci.2025.104130_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000506498","article-title":"High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis","volume":"143","author":"Sanchorawala","year":"2020","journal-title":"Acta Haematol"},{"issue":"6","key":"10.1016\/j.transci.2025.104130_bib24","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.hoc.2014.08.013","article-title":"High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis","volume":"28","author":"Sanchorawala","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"10.1016\/j.transci.2025.104130_bib25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bmt.2013.192","article-title":"Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement","volume":"49","author":"Girnius","year":"2014","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"10.1016\/j.transci.2025.104130_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bmt.1704344","article-title":"Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome","volume":"33","author":"Mollee","year":"2004","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.transci.2025.104130_bib27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.bmt.1705736","article-title":"Splenic rupture in a patient with plasma cell myeloma following G-CSF\/GM-CSF administration for stem cell transplantation and review of the literature","volume":"40","author":"Veerappan","year":"2007","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"10.1016\/j.transci.2025.104130_bib28","first-page":"2028","article-title":"Plerixafor dosing and administration in a patient with dialysis-dependent renal failure","volume":"44","author":"Gregory","year":"2010","journal-title":"Ann Pharm"},{"issue":"5","key":"10.1016\/j.transci.2025.104130_bib29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00277-018-3277-x","article-title":"A phase I\u2013II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia","volume":"97","author":"Mart\u00ednez-Cuadr\u00f3n","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.transci.2025.104130_bib30","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2014.318","article-title":"Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis","volume":"50","author":"Dhakal","year":"2015","journal-title":"Bone Marrow Transpl"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225000643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225000643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T02:27:28Z","timestamp":1749263248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050225000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1473050225000643"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2025.104130","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficiency and safety of granulocyte colony-stimulating factor combined with plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in light chain amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2025.104130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104130"}}